Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
Shares of gene-editing pioneer Intellia Therapeutics(NASDAQ:NTLA) have burst higher in response to the most exciting clinical trial results the biotech industry has produced in a long time. It’s still early, but it looks like the company found a way to…
